Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.63 |
| ▸ | WNT3A | P56704 | 1/20 | 0.63 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.52 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9348553 | 0.81 | NPC1 (0.72) | CTNNB1WNT3AROCK2ROCK1MEN1 | |
| SCHEMBL7157617 | 0.80 | RAB9A (0.59) | CTNNB1WNT3AROCK2ROCK1MEN1 | |
| SCHEMBL2571077 | 0.77 | ROCK2 (0.74) | ROCK2ROCK1MEN1KMT2ANPC1 | |
| SCHEMBL15968430 | 0.77 | CTNNB1 (1.00) | CTNNB1WNT3AROCK2ROCK1KMT2A | |
| SCHEMBL5623135 | 0.77 | NPC1 (0.55) | CTNNB1WNT3AROCK2ROCK1MEN1 | |
| SCHEMBL17593781 | 0.76 | PSMB8 (0.62) | ROCK2ROCK1MEN1KMT2ANPC1 | |
| SCHEMBL14129904 | 0.76 | MAPT (0.56) | CTNNB1WNT3AROCK2ROCK1MEN1 | |
| SCHEMBL17776529 | 0.76 | ROCK2 (0.71) | ROCK2ROCK1MEN1KMT2ANPC1 | |
| SCHEMBL4577230 | 0.76 | ROCK2 (0.67) | ROCK2ROCK1MEN1KMT2ANPC1 | |
| SCHEMBL17594115 | 0.75 | MEN1 (0.67) | ROCK2ROCK1MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633740-B1 | 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-11-09 | — | — | EP | disclosed |
| EP-1633740-B1 | 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-11-09 | — | — | EP | disclosed |
| US-7560467-B2 | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560467-B2 | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560467-B2 | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070099944-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-03 | — | — | US | disclosed |
| US-20070099944-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-03 | — | — | US | disclosed |
| US-20070099944-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099944-A1 | Chemical compounds | ROCK1, ROCK2, CIT | CTNNB1 2145/4885WNT3A 3801/4885ROCK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.